Ebvallo FDA Review: Can T Cells Treat Post-Transplant

What does the new FDA review mean for Ebvallo?

On October 14, Atara announced that its partner, Pierre Fabre Pharmaceuticals, had received FDA acceptance of the resubmitted application. The proposed indication covers adults and children aged two years and older with Epstein-Barr virus-positive post-transplant lymphoproliferative disease, or EBV+ PTLD, after at least one previous therapy. Tabelecleucel is marketed in Europe as Ebvallo. [Atara acceptance announcement](https://investors.atarabio.com/news-events/press-releases/detail/390/atara-biotherapeutics-reports-that-the-resubmitted) [European Medicines Agency overview](https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo)

This third review follows two unsuccessful applications. According to Atara, the initial FDA response identified manufacturing compliance deficiencies; the January 2026 response said those issues had been resolved but questioned whether the ALLELE trial adequately established effectiveness. The latest submission includes additional patients, longer follow-up and evidence from expanded access programs and European clinical use. Those additions broaden the evidence available to reviewers, although their inclusion does not establish that the earlier concerns have been resolved. [January regulatory update](https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business) [September resubmission announcement](https://investors.atarabio.com/news-events/press-releases/detail/389/atara-biotherapeutics-reports-that-the-tabelecleucel)

How does tabelecleucel target cancer after a transplant?

Transplant recipients need medicines that suppress immune activity to protect their transplanted organ or cells. That suppression can also weaken control of Epstein-Barr virus, allowing infected B cells to multiply and, in some patients, develop into cancer. Tabelecleucel uses T cells obtained from a donor and expanded in the laboratory after exposure to EBV-infected cells. The treatment aims to restore a targeted immune attack against the infected cancer cells. [EMA explanation of the treatment](https://www.ema.europa.eu/en/news/first-therapy-treat-transplant-patients-post-transplant-lymphoproliferative-disease)

In the initial 43-patient study summarized by the EMA, a complete or partial response occurred in 15 of 29 solid-organ transplant recipients and seven of 14 bone marrow transplant recipients. Together, that represents 22 responses, or approximately half the participants. A response means measurable cancer decreased or disappeared on assessment; it does not automatically establish a cure. These findings concern patients whose previous treatment had failed and should not be generalized to all transplant recipients or all EBV infections. [EMA study summary](https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo)

What uncertainties and safety risks still matter?

ALLELE is a single-arm trial, meaning participants receive the investigational therapy without a randomized comparison group. That design can identify tumor responses, but it makes it harder to determine how much treatment changes survival compared with alternative care. This limitation helps explain why additional follow-up matters: reviewers need to assess whether responses persist and whether the overall evidence supports a favorable benefit-risk balance. Atara's account of the January FDA decision specifically identified concerns about the trial's design, conduct and analysis. [Atara regulatory update](https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business)

European product information lists fever, diarrhea, fatigue and nausea among common adverse reactions. More serious reported reactions include inflammatory swelling around tumors, graft-versus-host disease and cytokine release syndrome. Graft-versus-host disease can also relate to changes in immunosuppressive treatment, complicating attribution. These risks require specialist monitoring and facilities capable of managing urgent complications. European authorization was granted under exceptional circumstances because the rarity of the disease limited the completeness of the available evidence; continued safety and effectiveness monitoring remains important. [European product information](https://www.ema.europa.eu/en/documents/product-information/ebvallo-epar-product-information_en.pdf) [EMA authorization assessment](https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo)